Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

Rising numbers of new COVID-19 cases might have investors anticipating strong demand for the company's 15-minute test.

Why Sorrento Therapeutics Is Climbing Today

Earlier this month we discussed that the stock of Sorrento Therapeutics (NASDAQ: SRNE) is best avoided given the large rally it has seen in a short time period. While SRNE stock declined over 8% from levels of $9.46 on June 14 to $8.69 on June 21, it has since rallied 14% to $9.90 now.

Is A Fall In Sorrento Therapeutics Stock Imminent After A 28% Rise In A Month?

Sorrento Therapeutics, Inc (NASDAQ:SRNE) shot up over 10% on June 24 after the company announced it received EUA approval and an import license from COFEPRIS for its rapid COVID-19 test, COVI-STIX. The stock is also a favorite of Reddit communities because of its underlying statistics.

Sorrento Therapeutics Forms Bullish Pattern, Options Traders Place Bets

The company is setting up a subsidiary to launch its COVID-19 test in Mexico.

Why Sorrento Therapeutics Stock Jumped 10.6% Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) is trading higher Thursday after the company received EUA approval and a product import license from COFEPRIS for its rapid COVID-19 test, COVI-STIX. COVI-STIX is a 15-minute rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients.

The News That Has Sorrento Therapeutics Trading Higher Today

SAN DIEGO, June 24, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that following its receipt of EUA approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under registration number “OFICIO: CAS/10720/2021”, it is establishing a local “Sorrento Mexico Ltd” subsidiary to manage commercial operations in Mexico.

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July

Sorrento is more than just a clinical stage biopharma company developing treatments for COVID, cancer and neurodegenerative diseases. It also generates revenues through contract manufacturing and sales of ZTlido used to treat Postherpetic Neuralgia.

Sorrento Therapeutics: More Than Just A Therapy For Those Who Don't Want To Be Stabbed With A Needle

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S. and Brazil. The company is expecting top-line clinical data at the end of the third quarter.

Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a broad multi-year Cooperative Research and Development Agreement (CRADA) with NAMRU-3. Under the terms of the agreement, NAMRU-3 will conduct surveillance and clinical validation research, and Sorrento will provide technical expertise and access to its portfolio of products to combat the SARS-CoV-2 and threats emerging due to variants of concern.

Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19

Sorrento Therapeutics Inc (NASDAQ: SRNE) has completed enrollment for its Phase 2 trial of Abivertinib in hospitalized COVID-19 patients in Brazil.  This study completion follows the recently completed enrollment of the U.S. Phase 2 clinical trial.

Sorrento Therapeutics Concludes Enrollment In Abivertinib Mid-Stage COVID-19 Trials In US, Brazil

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of enrollment for its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil. This study completion follows the recently completed enrollment of the US Phase 2 clinical trial.

Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21

Advanced Micro Devices

Yamana Gold

Coinbase

Enable Midstream Partners

Spirit Airlines

Electrameccanica

Although many indicators suggest the market is stretched, if you want to live dangerously, consider these high-risk, high-reward stocks. The post 7 High-Risk, High-Reward Stocks to Buy If You Have an Iron-Clad Stomach appeared first on InvestorPlace.

7 High-Risk, High-Reward Stocks to Buy If You Have an Iron-Clad Stomach

AMC Entertainment

Clover Health Investments

Castor Maritime Inc

GameStop

Canoo

Cenntro Electric Group

Meme stocks continue to be a thing, despite confounding analysts who are questioning whether they can survive on Reddit steam alone. The post 7 Meme Stocks to Avoid So You Don't Get Caught Holding the Bag appeared first on InvestorPlace.

7 Meme Stocks to Avoid So You Don't Get Caught Holding the Bag

The stock price of Sorrento Therapeutics (NASDAQ: SRNE), a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has seen a solid 49% rise over the last twenty-one trading sessions, led by multiple positive developments.

What's Next For Sorrento Therapeutics Stock After A Large 50% Rise In A Month?

The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.

Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

The stock price of Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 6.65% today. This is why it happened.

SRNE Stock Price Increased 6.65%: Why It Happened

Today, SRNE stock is on the move in a big way as investors price in two key announcements made by the company regarding clinical trials. The post SRNE Stock: The Big News Lifting Sorrento Therapeutics Today appeared first on InvestorPlace.

SRNE Stock: The Big News Lifting Sorrento Therapeutics Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology. Sofusa is a drug delivery platform that delivers biologic therapies through the skin and directly into the lymphatic system, potentially improving the efficacy and safety of immuno-oncology therapies.

Sorrento, Mayo Clinic Ink Research Pact For Ipilimumab-Delivering Sofusa In Melanoma Patients

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 trial evaluating COVI-DROPS in newly diagnosed COVID-19 infected patients. The application was submitted as a rolling application, and the MHRA cleared the study in less than a month from Sorrento's first submission to the MHRA.

Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK

Marathon Digital Holdings

If analysts are right, these stocks offer implied upside ranging from 105% to as much as 216%.

3 Stocks Wall Street Expects Will Double or Triple in 1 Year

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom's regulatory agency, has cleared Sorrento's COVI-DROPS product candidate for a Phase 2 efficacy trial. The application was submitted as a rolling application and the MHRA cleared the study in less than a month from Sorrento's first submission to the MHRA. The application was supported by the safety data from a healthy subject study completed in the US, which showed a safety profile comparable to placebo with doses up to 60 mg. In this study, there were no serious adverse effects or dose limiting toxicities and all adverse effects were mild in severity. The maximum tolerated dose was not reached.

Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology across multiple products and indications. Sofusa is a drug delivery platform which delivers biologic therapies through the skin and directly into the lymphatic system with potential to improve the efficacy and safety of immuno-oncology therapies. Targeting delivery to the lymphatics should also enable reduced dosing as compared to traditional systemic infusions or subcutaneous injections.

Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and development partner, will present posters at this year's American Society of Clinical Oncology (ASCO) meeting to be held June 5-6, 2021, releasing Phase 1 data for its HER2-ADC, A166. To generate this site-specific third generation antibody drug conjugate (ADC), Kelun partnered with Levena Biopharma, a wholly owned subsidiary of Sorrento, which provided the patent-protected technologies for the generation and production of A166, including (1) a proprietary small molecule toxin, Duostatin-5, a tubulin inhibitor, (2) K-Lock, a site-specific conjugation technology and (3) an enzymatically cleavable linker. Compared to its commercial competitors, A166 demonstrated a better safety profile in the initial study and potentially better efficacy, as shown in the overall response rate (ORR) of 71.4% (A166) at 6.0 mg/kg vs DS-8201, which has an ORR of 60.9% (DS-8201) at 5.4 mg/kg.

Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers

SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (“NextGenNK”) coordinated by KI.

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapid

News for Sorrento Therapeutics Inc Stock (SRNE)